Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited is a Japanese biopharmaceutical company operating in 80 countries.

For 2021, the company's research activities are aimed at creating new drugs in a number of therapeutic areas:

• oncology,
• gastroenterology,
• neurology and
• treatment of rare diseases,

as well as for the development of blood plasma preparations and vaccines.

Business in Russia

Main article: Takeda Russia

History

2022: Takeda acquires Nimbus Therapeutics for $6 billion

On December 13, 2022, Takeda entered into an agreement to acquire the allosteric tyrosine kinase 2 (TYK2) inhibitor Nimbus Therapeutics for $6 billion, NDI-034858. Oral therapy is used to treat a variety of autoimmune diseases. Read more here.

2019

$5.7 billion asset sale

In early May 2019, Takeda Pharmaceutical began selling off some assets totaling $5.7 billion to strategically simplify and optimize its service portfolio, while reducing borrowing and continuing to invest in its own developments.

Thus, the company has already sold the business of producing a patch based on fibrin glue TachoSil to its subsidiary Johnson & Johnson , the company. Ethicon The transaction value is $400 million. About 80 Takeda employees will move to work at Ethicon.

Johnson & Johnson buys surgical patch business from Takeda

TachoSil is a surgical patch used to stop bleeding. It is used in surgery to seal internal organs of local bleeding (hemostasis) and surface tissue. In 2017, sales of this product amounted to $155 million. Although Ethicon buys assets and licenses for the patch, Takeda retains the plant in Linz (Austria), which produces TachoSil.

Takeda Pharmaceutical also decided to sell the Xiidra lifitegrast ophthalmic solution business, which will now be included in Novartis' portfolio . The advance payment will amount to $3.4 billion, in the future, upon reaching unnamed targets, Novartis will pay Takeda another $1.9 billion in phased payments. Along with the drug being purchased, Novartis will also hire about 400 Takeda employees whose work was related to the production of Xiidra.

Xiidra lifitegrast is a drug to treat the symptoms of dry eye syndrome, preventing permanent damage to the cornea of the eye and loss of vision. At the end of 2018, Xiidra sales amounted to $387 million. By 2022, according to GlobalData, the drug will become one of the most significant on the pharmacological market and by 2025 will reach annual sales of $1.2 billion. Strategically, the acquisition will complement Novartis' portfolio of eye disease drugs.

Both deals are expected to close in the second half of 2019. ^[1]

The average salary in the Lithuanian division in June is 16,600 euros

According to the Lithuanian Social Insurance Fund (SODRA), in June 2019, 6 employees of the pharmaceutical Lithuanian division of Takeda (Takeda, UAB) received an average salary of 16,600 euros. In May, employees of this company received an average of 4,200 euros "on paper."^[2]

2013: 12th place in the global market

Takeda Pharmaceutical is considered one of the leading pharmaceutical companies not only in Japan, but throughout the world.

As of December 2013, Takeda Pharmaceutical ranks 12th in the pharmacological industry rating table, ahead of leading companies in many countries of Asia, Europe and North America. The company has opened its representative offices in more than 70 countries, including China, Latin America and the CIS countries.

2011: Purchase of Swiss Nycomed for €9.6 billion

In September 2011, Takeda Pharmaceutical acquired the Swiss company Nycomed for €9.6 billion.

1781: Chobei Takeda Begins Trade in Traditional Japanese and Chinese Medicines

The history of the company dates back to the end of the 18th century, when a representative of an old and noble family, 32-year-old Chobei Takeda founded a small intermediary company in Osaka selling traditional Japanese and Chinese medicines.

Notes